00000nam 2200000zi 4500 9.947789 CaOODSP 20250428091713 m o d f cr mn||||||||| 250206e20250313onc ob f000 0 eng d 9780660756226 (statement) 9780660756233 (summary) CaOODSP eng rda CaOODSP n-cn--- HP40-384/2025E-PDF HP40-384/2025-1E-PDF Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults including the expanded use of RSVPreF3 for individuals 50-59 years of age and use of the new mRNA-1345 vaccine. Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, March 13, 2025. ©2025 1 online resource (51 pages) + summary (5 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Directives mises à jour sur les vaccins contre le virus respiratoire syncytial (VRS) chez les personnes âgées, y compris l'utilisation élargie du VRSPreF3 chez les individus de 50 à 59 ans et l'utilisation du nouveau vaccin ARNm-1345. On cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). "Pub.: 240852"--Page 2. "Pub.: 240854"--Page 2 (summary). Includes bibliographical references (pages 47-51). Respiratory syncytial virus Vaccination Government policy Canada. Viral vaccines Government policy Canada. Immunization of older people Government policy Canada. Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. Directives mises à jour sur les vaccins contre le virus respiratoire syncytial (VRS) chez les personnes âgées, y compris l'utilisation élargie du VRSPreF3 chez les individus de 50 à 59 ans et l'utilisation du nouveau vaccin ARNm-1345. (CaOODSP)9.947790 PDF 871 KB https://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-384-2025-eng.pdf (statement) PDF 222 KB https://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-384-2025-1-eng.pdf (summary) HTML N/A https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpref3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html (statement) HTML N/A https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpref3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html (summary)